Columbus, OH, United States
Columbus, OH, United States

Time filter

Source Type

News Article | February 16, 2017
Site: www.accesswire.com

TORONTO, ON / ACCESSWIRE / February 16, 2017 / Wi2Wi Corporation (Wi2Wi or the Company) (TSX-V: YTY), announces that Mr. Daniel Phelan has resigned as a director and Chairman of the Board of Directors. Mr. Michael R. Sonnenreich and Fraser C. Henderson Sr., M.D have joined the Board of Directors and Mr. Sonnenreich was elected as the Chairman of the Board of Directors. Mr. Sonnenreich is a lawyer and a philanthropist and has extensive management experiences in various industries; Technology, Pharmaceutical and Global Marketing. He is an active stake holder and advisor to several national and international companies. Currently, Mr. Sonnenreich is the Chairman of the Board of Kikaku America International, and Vice Chairman of PharMa International Corporation of Tokyo, Japan. He is a graduate of the University of Wisconsin, the University of Madrid, Spain, and Harvard University Law School. In the past twelve years Mr. Sonnenreich has served as a board member and trustee of numerous important companies and universities, including Williams Creek Explorations, Vancouver, British Columbia, Canada; Wi2Wi, San Jose, California; Tyhee Development Corp. Ltd., Vancouver, British Columbia, Canada; Les Aliments SoYummi, Inc., Montreal, Canada; the ABD American Capital Market Funds; the Integra Fund; Continental Steel Inc.; Amorfix Life Sciences Ltd. (now Promis Neurosciences), Vancouver, British Columbia, Canada; Scientific American; and Medical Tribune International. Mr. Sonnenreich has had long-term involvement with many nonprofit institutions. These include the Washington National Opera (President 1996-98; 2002-2006); D.C. Jazz Festival (Chairman, 2010-2014); Sackler/Freer Galleries of Art (Smithsonian Institution), D.C.; Commission on the Arts and Humanities (Mayoral Appointment as Commissioner, 2008-2011); the Johns Hopkins University School of Advanced International Studies; the New England Conservatory of Music; the North Carolina Museum of Art Foundation; the University of Virginia Art Museum; Clark University; the Maret School; and the Richard Tucker Music Foundation. Mr. Sonnenreich served as President of the National Coordinating Council on Drug Education. In 2008, he was named Distinguished Washingtonian by the University Club of Washington, D.C. He previously served in government in the Department of Justice and was appointed Executive Director of the National Commission on Marijuana and Drug Abuse. Dr. Henderson is a world renowned Board-certified Neurological Surgeon and a retired US Navy Commander. He has received both his bachelor's and Medical degree from the University of Virginia, Charlottesville Virginia. He completed his fellowship in Craniospinal surgery under Professor Alan Crockard at The National Hospital for Neurology and Neurosurgery, Queen Square, London. As Part of his active duty obligations; Dr. Henderson was the Director of Spine at National Naval Medical Center, Bethesda, MD and was Brigade Neurosurgeon for the 4th Marine Expeditionary Brigade in Desert Shield and Desert Storm during the 1st Gulf War. Finishing his tour with the US Navy, Commander Henderson joined Georgetown University, in Washington D.C. as Director of Neurosurgery of the Spine and Cranio-cervical Junction. He was Co-Director of the Lombardi Neuro-Oncology Division, Co-Director of the CyberKnife Radiosurgery Center, and Medical Director of the Neuroscience Nursing Units. He was Professor of Neurosurgery and Radiology at Georgetown University, where he was active in advancing CyberKnife radiosurgery for treatment of chordoma and other complex spinal tumors. He is the Director of Neurosurgery at Doctors Hospital and Director of the Chiari Center of Excellence, where he is focused on the development of the understanding and treatment of deformity induced injury to the brainstem and spinal cord in Chiari Malformation and Ehlers Danlos Syndrome. Dr. Henderson developed intellectual property for three inventions relating to spinal radiosurgery and spinal cancer, including the TPS® -Telescopic Plate Spacer- a vertebral replacement device for metastatic disease and was Principal Investigator in the translational development of a radio-sensitizing drug, and a drug to block the malignant invasiveness of Glioblastoma Multiforme. He is an inventor of 11 devices and concepts relating to disorders of the brainstem and spinal cord, and has published over 50 peer reviewed articles and book chapters, and given over 120 invited lectures with a focus on craniocervical disorders, Chiari malformation, cancer, radiosurgery and unusual problems of the spine "We are excited to have both Mr. Sonnenreich and Mr. Henderson in the Board. Their vast experience and expertise will definitely guide the company into the successful future," said Zachariah Mathews, President and CEO of Wi2Wi. "The Board expresses its profound appreciation to Mr. Daniel Phelan for the business and financial expertise he brought to the board of directors over the past three years and helping the management of the company," said the Chairman of the Board Mr. Michael Sonnenreich. For further information, please contact: Essentially, IoT and M2M describe the network of physical objects or "things" embedded with electronics, software, sensors, and network connectivity, which enables these objects to collect and exchange data. Driven by several factors including the growth in the availability of Broadband Internet, which reduces the cost of connecting, and the related increase in Wi-Fi capabilities as well as sensors built into myriad technologies, this has been described as the "perfect storm" for the IoT. Almost any device with an on and off switch that can be connected to the Internet (and/or to each other) - anything from cell phones, coffee makers, washing machines, headphones, lamps, wearable devices, cars, as well as machine components in the engine of a jet airplane or the drill of an oil rig. According to analyst firm Gartner, by 2020 there will be over 26 billion connected devices. Others think this figure could be too conservative by a factor of four. Wi2Wi is a vertically-integrated technology company which designs, manufactures and markets high performance, low power wireless connectivity solutions, global navigation satellite system (GNSS) modules, and frequency control devices. The Company's products and services address numerous applications in the markets of Internet of Things (IoT), Machine to Machine (M2M), Avionics, Space, and Government Sponsored Projects. Wi2Wi's products and value-added services provide highly integrated, rugged, robust, and reliable multiprotocol wireless actuators with embedded software, along with customized timing and frequency control devices for customers, worldwide. The Company was founded in 2005 and is strategically headquartered in San Jose, California with satellite offices in Middleton, Wisconsin and Hyderabad, India. Wi2Wi's manufacturing operations, its laboratory for reliability and quality control, together with design and engineering for timing and frequency control devices are located in Middleton, WI. The branch office, located in Hyderabad, India, focuses on the development of wireless connectivity; both hardware and software. Wi2Wi's strategic objective is to service the unique needs of each customer by providing end to end wireless integration solutions and highly customizable timing and frequency control devices. Wi2Wi distinguishes itself from commodity grade products, with best in the market performance, highly reliable, low power wireless connectivity products with integrated software that supports broader temperature ranges and a longer product life cycle. Furthermore, Wi2Wi's end to end product solutions helps the customer substantially reduce their end product expense, certification cost, and overall R&D investment, in addition to substantially reducing the time to market. Wi2Wi has partnered with best in class global leaders in technology, manufacturing, and sales. The Company uses a wide network of manufacturer's representatives, worldwide, to promote its products and services, and has partnered with world class distributors for the fulfillment of orders along with direct sales. Forward-Looking Statements: This news release contains certain forward-looking statements, including management's assessment of future plans and operations, and the timing thereof, that involve substantial known and unknown risks and uncertainties, certain of which are beyond the Company's control. Such risks and uncertainties include, without limitation, risks associated with the ability to access sufficient capital, the impact of general economic conditions in Canada, the United States and overseas, industry conditions, stock market volatility. The Company's actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what benefits, including the amount of proceeds, that the Company will derive there from. Readers are cautioned that the foregoing list of factors is not exhaustive. Additional information on these and other factors that could affect the Company's operations and financial results are included in reports on file with Canadian securities regulatory authorities and may be accessed through the SEDAR website (www.sedar.com). Forward-looking statements are made based on management's beliefs, estimates and opinions on the date the statements are made and the Company undertakes no obligation to update forward-looking statements and if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable law. All subsequent forward-looking statements, whether written or oral, attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Furthermore, the forward-looking statements contained in this news release are made as at the date of this news release and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


News Article | October 28, 2016
Site: www.marketwired.com

MIAMI, FL--(Marketwired - October 28, 2016) - Dr. Sergio Gonzalez-Arias, chief of neurological surgery at Baptist Hospital and chair of the Department of Neuroscience at FIU's Herbert Wertheim College of Medicine, will join the College of Medicine's executive team as executive associate dean for clinical affairs. Gonzalez-Arias, who will begin his new position with the Herbert Wertheim College of Medicine in January 2017, will oversee all clinical functions at the College of Medicine, including the students' clinical experience; all strategic partnerships with hospitals and other clinical sites where students perform their clinical rotations; and development of Graduate Medical Education. "We have been fortunate to work with Dr. Gonzalez-Arias as a key member of our faculty since 2010. Now he brings to his new position a wealth of clinical experience that will add to the development of clinical programs to the College of Medicine," said Dr. John A. Rock, founding dean of the Herbert Wertheim College of Medicine and FIU senior vice president for health affairs. Wayne Brackin, executive vice president and chief operating officer for Baptist Health South Florida, said Gonzalez-Arias has made important contributions to the field of neuroscience. "Dr. Gonzalez-Arias is a well-respected neurosurgeon who has advanced his profession and expanded the comprehensive neuroscience offerings at Baptist Health," Brackin said. "As the founding medical director of Baptist Health Neuroscience Center he has developed and implemented surgical and technological advancements that have had a profound impact on our patients." Gonzalez-Arias is the founding and current medical director of Baptist Health Neuroscience Center. He has served as chief of Baptist Hospital's Department of Surgery and is a past president of the medical staff. He is a fellow of the American Association of Neurological Surgeons and the American College of Surgeons. He served as chair of the international committee of the Joint Council of State Neurosurgical Societies and is a past president of the Florida Neurological Society. "I am excited about this new opportunity at the FIU College of Medicine, which will allow me to continue building on its impressive growth, which I am honored to have been part of for several years," Gonzalez-Arias said. "In keeping with the best practice of a multidisciplinary approach to medicine, I look forward to collaborating with the university's hospital and community partners to research, innovate and continue making a significant positive impact on medical education and healthcare in our community." Dr. Gonzalez-Arias is a graduate of the University of Zaragoza (Spain) and completed his residencies at Rush-Presbyterian St. Luke's Medical Center and the University of Miami/Jackson Memorial Hospital. About Baptist Health South Florida: Baptist Health South Florida is the largest healthcare organization in the region, with seven hospitals (Baptist Hospital, Baptist Children's Hospital, Doctors Hospital, Homestead Hospital, Mariners Hospital, South Miami Hospital and West Kendall Baptist Hospital), nearly 50 outpatient and urgent care facilities, Baptist Health Medical Group, Baptist Health Quality Network and internationally renowned centers of excellence. The not-for-profit, faith-based Baptist Health has approximately 16,000 employees and 2,300 affiliated physicians. Baptist Health South Florida has been recognized as one of the 100 Best Companies to Work For in America and as one of the World's Most Ethical Companies. For more information, visit BaptistHealth.net and connect with us on Facebook at facebook.com/BaptistHealthSF and on Twitter and Instagram @BaptistHealthSF. About The FIU Herbert Wertheim College of Medicine: The Herbert Wertheim College of Medicine was approved in 2006 by the Florida Board of Governors and the Florida Legislature, and in February 2013 the medical degree program received full accreditation from the Liaison Committee for Medical Education. The College graduated its inaugural class on April 29, 2013. Among the innovative elements of the HWCOM is a program called Green Family Foundation NeighborhoodHELP™ that sends teams of medical students along with their counterparts in social work, nursing, and law into the community. The College of Medicine's mission is to lead the next generation of medical education and improve the quality of health care available to the South Florida community. For more information visit http://medicine.fiu.edu/ About FIU: Florida International University is classified by Carnegie as a "R1: Doctoral Universities - Highest Research Activity" and recognized as a Carnegie Community Engaged university. It is a public research university with colleges and schools that offers bachelor's, master's and doctoral programs in fields such as business engineering, computer science, international relations, architecture, law and medicine. As one of South Florida's anchor institutions, FIU contributes almost $9 billion each year to the local economy and is ranked second in Florida in Forbes Magazine's "America's Best Employers" list. FIU graduates are consistently among the highest paid college graduates in Florida and are among the leaders of public and private organizations throughout South Florida. FIU is Worlds Ahead in finding solutions to the most challenging problems of our time. FIU emphasizes research as a major component of its mission with multiple state-of-the-art research facilities including the Wall of Wind Research and Testing Facility, FIU's Medina Aquarius Program and the Advanced Materials Engineering Research Institute. FIU has awarded more than 220,000 degrees and enrolls more than 54,000 students in two campuses and centers including FIU Downtown on Brickell, FIU@I-75, the Miami Beach Urban Studios, and Tianjin, China. FIU also supports artistic and cultural engagement through its three museums: Patricia & Phillip Frost Art Museum, the Wolfsonian-FIU, and the Jewish Museum of Florida-FIU. FIU is a member of Conference USA and more than 400 student-athletes participating in 18 sports. For more information about FIU, visit http://www.fiu.edu/.


News Article | February 16, 2017
Site: marketersmedia.com

TORONTO, ON / ACCESSWIRE / February 16, 2017 / Wi2Wi Corporation (Wi2Wi or the Company) (TSX-V: YTY), announces that Mr. Daniel Phelan has resigned as a director and Chairman of the Board of Directors. Mr. Michael R. Sonnenreich and Fraser C. Henderson Sr., M.D have joined the Board of Directors and Mr. Sonnenreich was elected as the Chairman of the Board of Directors. Mr. Sonnenreich is a lawyer and a philanthropist and has extensive management experiences in various industries; Technology, Pharmaceutical and Global Marketing. He is an active stake holder and advisor to several national and international companies. Currently, Mr. Sonnenreich is the Chairman of the Board of Kikaku America International, and Vice Chairman of PharMa International Corporation of Tokyo, Japan. He is a graduate of the University of Wisconsin, the University of Madrid, Spain, and Harvard University Law School. In the past twelve years Mr. Sonnenreich has served as a board member and trustee of numerous important companies and universities, including Williams Creek Explorations, Vancouver, British Columbia, Canada; Wi2Wi, San Jose, California; Tyhee Development Corp. Ltd., Vancouver, British Columbia, Canada; Les Aliments SoYummi, Inc., Montreal, Canada; the ABD American Capital Market Funds; the Integra Fund; Continental Steel Inc.; Amorfix Life Sciences Ltd. (now Promis Neurosciences), Vancouver, British Columbia, Canada; Scientific American; and Medical Tribune International. Mr. Sonnenreich has had long-term involvement with many nonprofit institutions. These include the Washington National Opera (President 1996-98; 2002-2006); D.C. Jazz Festival (Chairman, 2010-2014); Sackler/Freer Galleries of Art (Smithsonian Institution), D.C.; Commission on the Arts and Humanities (Mayoral Appointment as Commissioner, 2008-2011); the Johns Hopkins University School of Advanced International Studies; the New England Conservatory of Music; the North Carolina Museum of Art Foundation; the University of Virginia Art Museum; Clark University; the Maret School; and the Richard Tucker Music Foundation. Mr. Sonnenreich served as President of the National Coordinating Council on Drug Education. In 2008, he was named Distinguished Washingtonian by the University Club of Washington, D.C. He previously served in government in the Department of Justice and was appointed Executive Director of the National Commission on Marijuana and Drug Abuse. Dr. Henderson is a world renowned Board-certified Neurological Surgeon and a retired US Navy Commander. He has received both his bachelor's and Medical degree from the University of Virginia, Charlottesville Virginia. He completed his fellowship in Craniospinal surgery under Professor Alan Crockard at The National Hospital for Neurology and Neurosurgery, Queen Square, London. As Part of his active duty obligations; Dr. Henderson was the Director of Spine at National Naval Medical Center, Bethesda, MD and was Brigade Neurosurgeon for the 4th Marine Expeditionary Brigade in Desert Shield and Desert Storm during the 1st Gulf War. Finishing his tour with the US Navy, Commander Henderson joined Georgetown University, in Washington D.C. as Director of Neurosurgery of the Spine and Cranio-cervical Junction. He was Co-Director of the Lombardi Neuro-Oncology Division, Co-Director of the CyberKnife Radiosurgery Center, and Medical Director of the Neuroscience Nursing Units. He was Professor of Neurosurgery and Radiology at Georgetown University, where he was active in advancing CyberKnife radiosurgery for treatment of chordoma and other complex spinal tumors. He is the Director of Neurosurgery at Doctors Hospital and Director of the Chiari Center of Excellence, where he is focused on the development of the understanding and treatment of deformity induced injury to the brainstem and spinal cord in Chiari Malformation and Ehlers Danlos Syndrome. Dr. Henderson developed intellectual property for three inventions relating to spinal radiosurgery and spinal cancer, including the TPS® -Telescopic Plate Spacer- a vertebral replacement device for metastatic disease and was Principal Investigator in the translational development of a radio-sensitizing drug, and a drug to block the malignant invasiveness of Glioblastoma Multiforme. He is an inventor of 11 devices and concepts relating to disorders of the brainstem and spinal cord, and has published over 50 peer reviewed articles and book chapters, and given over 120 invited lectures with a focus on craniocervical disorders, Chiari malformation, cancer, radiosurgery and unusual problems of the spine "We are excited to have both Mr. Sonnenreich and Mr. Henderson in the Board. Their vast experience and expertise will definitely guide the company into the successful future," said Zachariah Mathews, President and CEO of Wi2Wi. "The Board expresses its profound appreciation to Mr. Daniel Phelan for the business and financial expertise he brought to the board of directors over the past three years and helping the management of the company," said the Chairman of the Board Mr. Michael Sonnenreich. For further information, please contact: Essentially, IoT and M2M describe the network of physical objects or "things" embedded with electronics, software, sensors, and network connectivity, which enables these objects to collect and exchange data. Driven by several factors including the growth in the availability of Broadband Internet, which reduces the cost of connecting, and the related increase in Wi-Fi capabilities as well as sensors built into myriad technologies, this has been described as the "perfect storm" for the IoT. Almost any device with an on and off switch that can be connected to the Internet (and/or to each other) - anything from cell phones, coffee makers, washing machines, headphones, lamps, wearable devices, cars, as well as machine components in the engine of a jet airplane or the drill of an oil rig. According to analyst firm Gartner, by 2020 there will be over 26 billion connected devices. Others think this figure could be too conservative by a factor of four. Wi2Wi is a vertically-integrated technology company which designs, manufactures and markets high performance, low power wireless connectivity solutions, global navigation satellite system (GNSS) modules, and frequency control devices. The Company's products and services address numerous applications in the markets of Internet of Things (IoT), Machine to Machine (M2M), Avionics, Space, and Government Sponsored Projects. Wi2Wi's products and value-added services provide highly integrated, rugged, robust, and reliable multiprotocol wireless actuators with embedded software, along with customized timing and frequency control devices for customers, worldwide. The Company was founded in 2005 and is strategically headquartered in San Jose, California with satellite offices in Middleton, Wisconsin and Hyderabad, India. Wi2Wi's manufacturing operations, its laboratory for reliability and quality control, together with design and engineering for timing and frequency control devices are located in Middleton, WI. The branch office, located in Hyderabad, India, focuses on the development of wireless connectivity; both hardware and software. Wi2Wi's strategic objective is to service the unique needs of each customer by providing end to end wireless integration solutions and highly customizable timing and frequency control devices. Wi2Wi distinguishes itself from commodity grade products, with best in the market performance, highly reliable, low power wireless connectivity products with integrated software that supports broader temperature ranges and a longer product life cycle. Furthermore, Wi2Wi's end to end product solutions helps the customer substantially reduce their end product expense, certification cost, and overall R&D investment, in addition to substantially reducing the time to market. Wi2Wi has partnered with best in class global leaders in technology, manufacturing, and sales. The Company uses a wide network of manufacturer's representatives, worldwide, to promote its products and services, and has partnered with world class distributors for the fulfillment of orders along with direct sales. Forward-Looking Statements: This news release contains certain forward-looking statements, including management's assessment of future plans and operations, and the timing thereof, that involve substantial known and unknown risks and uncertainties, certain of which are beyond the Company's control. Such risks and uncertainties include, without limitation, risks associated with the ability to access sufficient capital, the impact of general economic conditions in Canada, the United States and overseas, industry conditions, stock market volatility. The Company's actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what benefits, including the amount of proceeds, that the Company will derive there from. Readers are cautioned that the foregoing list of factors is not exhaustive. Additional information on these and other factors that could affect the Company's operations and financial results are included in reports on file with Canadian securities regulatory authorities and may be accessed through the SEDAR website (www.sedar.com). Forward-looking statements are made based on management's beliefs, estimates and opinions on the date the statements are made and the Company undertakes no obligation to update forward-looking statements and if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable law. All subsequent forward-looking statements, whether written or oral, attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Furthermore, the forward-looking statements contained in this news release are made as at the date of this news release and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. TORONTO, ON / ACCESSWIRE / February 16, 2017 / Wi2Wi Corporation (Wi2Wi or the Company) (TSX-V: YTY), announces that Mr. Daniel Phelan has resigned as a director and Chairman of the Board of Directors. Mr. Michael R. Sonnenreich and Fraser C. Henderson Sr., M.D have joined the Board of Directors and Mr. Sonnenreich was elected as the Chairman of the Board of Directors. Mr. Sonnenreich is a lawyer and a philanthropist and has extensive management experiences in various industries; Technology, Pharmaceutical and Global Marketing. He is an active stake holder and advisor to several national and international companies. Currently, Mr. Sonnenreich is the Chairman of the Board of Kikaku America International, and Vice Chairman of PharMa International Corporation of Tokyo, Japan. He is a graduate of the University of Wisconsin, the University of Madrid, Spain, and Harvard University Law School. In the past twelve years Mr. Sonnenreich has served as a board member and trustee of numerous important companies and universities, including Williams Creek Explorations, Vancouver, British Columbia, Canada; Wi2Wi, San Jose, California; Tyhee Development Corp. Ltd., Vancouver, British Columbia, Canada; Les Aliments SoYummi, Inc., Montreal, Canada; the ABD American Capital Market Funds; the Integra Fund; Continental Steel Inc.; Amorfix Life Sciences Ltd. (now Promis Neurosciences), Vancouver, British Columbia, Canada; Scientific American; and Medical Tribune International. Mr. Sonnenreich has had long-term involvement with many nonprofit institutions. These include the Washington National Opera (President 1996-98; 2002-2006); D.C. Jazz Festival (Chairman, 2010-2014); Sackler/Freer Galleries of Art (Smithsonian Institution), D.C.; Commission on the Arts and Humanities (Mayoral Appointment as Commissioner, 2008-2011); the Johns Hopkins University School of Advanced International Studies; the New England Conservatory of Music; the North Carolina Museum of Art Foundation; the University of Virginia Art Museum; Clark University; the Maret School; and the Richard Tucker Music Foundation. Mr. Sonnenreich served as President of the National Coordinating Council on Drug Education. In 2008, he was named Distinguished Washingtonian by the University Club of Washington, D.C. He previously served in government in the Department of Justice and was appointed Executive Director of the National Commission on Marijuana and Drug Abuse. Dr. Henderson is a world renowned Board-certified Neurological Surgeon and a retired US Navy Commander. He has received both his bachelor's and Medical degree from the University of Virginia, Charlottesville Virginia. He completed his fellowship in Craniospinal surgery under Professor Alan Crockard at The National Hospital for Neurology and Neurosurgery, Queen Square, London. As Part of his active duty obligations; Dr. Henderson was the Director of Spine at National Naval Medical Center, Bethesda, MD and was Brigade Neurosurgeon for the 4th Marine Expeditionary Brigade in Desert Shield and Desert Storm during the 1st Gulf War. Finishing his tour with the US Navy, Commander Henderson joined Georgetown University, in Washington D.C. as Director of Neurosurgery of the Spine and Cranio-cervical Junction. He was Co-Director of the Lombardi Neuro-Oncology Division, Co-Director of the CyberKnife Radiosurgery Center, and Medical Director of the Neuroscience Nursing Units. He was Professor of Neurosurgery and Radiology at Georgetown University, where he was active in advancing CyberKnife radiosurgery for treatment of chordoma and other complex spinal tumors. He is the Director of Neurosurgery at Doctors Hospital and Director of the Chiari Center of Excellence, where he is focused on the development of the understanding and treatment of deformity induced injury to the brainstem and spinal cord in Chiari Malformation and Ehlers Danlos Syndrome. Dr. Henderson developed intellectual property for three inventions relating to spinal radiosurgery and spinal cancer, including the TPS® -Telescopic Plate Spacer- a vertebral replacement device for metastatic disease and was Principal Investigator in the translational development of a radio-sensitizing drug, and a drug to block the malignant invasiveness of Glioblastoma Multiforme. He is an inventor of 11 devices and concepts relating to disorders of the brainstem and spinal cord, and has published over 50 peer reviewed articles and book chapters, and given over 120 invited lectures with a focus on craniocervical disorders, Chiari malformation, cancer, radiosurgery and unusual problems of the spine "We are excited to have both Mr. Sonnenreich and Mr. Henderson in the Board. Their vast experience and expertise will definitely guide the company into the successful future," said Zachariah Mathews, President and CEO of Wi2Wi. "The Board expresses its profound appreciation to Mr. Daniel Phelan for the business and financial expertise he brought to the board of directors over the past three years and helping the management of the company," said the Chairman of the Board Mr. Michael Sonnenreich. For further information, please contact: Essentially, IoT and M2M describe the network of physical objects or "things" embedded with electronics, software, sensors, and network connectivity, which enables these objects to collect and exchange data. Driven by several factors including the growth in the availability of Broadband Internet, which reduces the cost of connecting, and the related increase in Wi-Fi capabilities as well as sensors built into myriad technologies, this has been described as the "perfect storm" for the IoT. Almost any device with an on and off switch that can be connected to the Internet (and/or to each other) - anything from cell phones, coffee makers, washing machines, headphones, lamps, wearable devices, cars, as well as machine components in the engine of a jet airplane or the drill of an oil rig. According to analyst firm Gartner, by 2020 there will be over 26 billion connected devices. Others think this figure could be too conservative by a factor of four. Wi2Wi is a vertically-integrated technology company which designs, manufactures and markets high performance, low power wireless connectivity solutions, global navigation satellite system (GNSS) modules, and frequency control devices. The Company's products and services address numerous applications in the markets of Internet of Things (IoT), Machine to Machine (M2M), Avionics, Space, and Government Sponsored Projects. Wi2Wi's products and value-added services provide highly integrated, rugged, robust, and reliable multiprotocol wireless actuators with embedded software, along with customized timing and frequency control devices for customers, worldwide. The Company was founded in 2005 and is strategically headquartered in San Jose, California with satellite offices in Middleton, Wisconsin and Hyderabad, India. Wi2Wi's manufacturing operations, its laboratory for reliability and quality control, together with design and engineering for timing and frequency control devices are located in Middleton, WI. The branch office, located in Hyderabad, India, focuses on the development of wireless connectivity; both hardware and software. Wi2Wi's strategic objective is to service the unique needs of each customer by providing end to end wireless integration solutions and highly customizable timing and frequency control devices. Wi2Wi distinguishes itself from commodity grade products, with best in the market performance, highly reliable, low power wireless connectivity products with integrated software that supports broader temperature ranges and a longer product life cycle. Furthermore, Wi2Wi's end to end product solutions helps the customer substantially reduce their end product expense, certification cost, and overall R&D investment, in addition to substantially reducing the time to market. Wi2Wi has partnered with best in class global leaders in technology, manufacturing, and sales. The Company uses a wide network of manufacturer's representatives, worldwide, to promote its products and services, and has partnered with world class distributors for the fulfillment of orders along with direct sales. Forward-Looking Statements: This news release contains certain forward-looking statements, including management's assessment of future plans and operations, and the timing thereof, that involve substantial known and unknown risks and uncertainties, certain of which are beyond the Company's control. Such risks and uncertainties include, without limitation, risks associated with the ability to access sufficient capital, the impact of general economic conditions in Canada, the United States and overseas, industry conditions, stock market volatility. The Company's actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what benefits, including the amount of proceeds, that the Company will derive there from. Readers are cautioned that the foregoing list of factors is not exhaustive. Additional information on these and other factors that could affect the Company's operations and financial results are included in reports on file with Canadian securities regulatory authorities and may be accessed through the SEDAR website (www.sedar.com). Forward-looking statements are made based on management's beliefs, estimates and opinions on the date the statements are made and the Company undertakes no obligation to update forward-looking statements and if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable law. All subsequent forward-looking statements, whether written or oral, attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Furthermore, the forward-looking statements contained in this news release are made as at the date of this news release and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


News Article | February 24, 2017
Site: www.prweb.com

Dr. Ronald E. Hawkins, vice president for academic affairs and provost of Liberty University, has officially announced the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean of Liberty University College of Osteopathic Medicine (LUCOM), beginning April 10. Dr. Bell comes to Liberty from the Ohio University Heritage College of Osteopathic Medicine (OU-HCOM), where he has most recently served as assistant dean for undergraduate and graduate medical education. “I believe that Dr. Bell incarnates all of the traits that I envisioned finding in a new dean for Liberty University College of Osteopathic Medicine,” Hawkins said. “He combines a passion for osteopathic medicine with the depth of experience, knowledge, and spiritual sensitivity required for leading LUCOM forward into what I believe will be a very bright future.” Joining him in Lynchburg will be his wife, Irene, a seasoned attorney, financial planning expert, and super mom to many. “I’m ready to serve God’s greater purpose as a steward of the college," Bell said. "Together we shall pursue excellence with a servant’s heart.” Bell is a graduate of Hamilton College and obtained his osteopathic medical degree from the University of New England College of Osteopathic Medicine. He earned his M.B.A. from Ohio University College of Business. He is board-certified in both family medicine and emergency medicine. After completing his residencies, Bell began his first staff appointment as the medical director of the Emergency Department at Doctors Hospital, Columbus, Ohio. No stranger to academic leadership, Bell established the Emergency Medicine Residence at Doctors Hospital in 1991. He became a full-time assistant dean at OU-HCOM in 1995. From 2002 to 2006, he was a residency program inspector for the American Osteopathic Association (AOA). Bell was appointed clinical professor of Emergency Medicine in 2002 and awarded the distinction of Master Clinical Faculty in 2010. For the past seven years, he has been an active committee member for the National Board of Osteopathic Medical Examiners. Dr. Bell has been recognized for his outstanding contributions throughout his academic and medical career. He has received the Meritorious Service Award as a Pioneer in Emergency Medicine from Doctors Hospital; the National Teaching Faculty Award from the American College of Emergency Physicians (ACEP); and the William I. Linder, DO, Advocate Award from the Columbus Osteopathic Association. He also received the Lifetime Achievement Award for his contributions to emergency medicine from the American College of Osteopathic Emergency Physicians (ACOEP). Bell has completed the National Health Policy Fellowship, a certificate program in health policy coordinated by the AOA and OU-HCOM. The Fellowship is a yearlong leadership training program designed for osteopathic physicians to further their skills in analyzing and implementing health policies on the local, state, and national levels with the purpose of increasing access to affordable, quality health care. Dr. Bell has served in many national leadership positions, including president of the Ohio Osteopathic Association (OOA) in 2002 and 2003, president of ACEP (OH-chapter) in 2005 and 2006, and most recently as president of the ACOEP in 2006 and 2008. He continues to serve on a variety of state and national bureaus as well as political committees. Currently, Dr. Bell is serving as Chair of the Board for the Centers of Osteopathic Research and Education (CORE) at OU-HCOM. In commenting on Bell’s decision to join Liberty University, President Jerry Falwell said, “Liberty University College of Osteopathic Medicine is proud to welcome Dr. Peter Bell as its second dean. We believe Dr. Bell is uniquely qualified as an educator and an innovator to lead LUCOM at this critical juncture in the young college’s existence.” Interim LUCOM Dean Dr. David Klink said, “Everyone at LUCOM is very excited about Dr. Bell becoming the new dean. I think that God has uniquely prepared him for this role. His experience, educational background, and spiritual depth will enable him to lead the college to achieve great things for our students, their future patients, and God’s glory.” About Liberty University  Liberty University, founded in 1971, is the largest private, nonprofit university in the nation, the largest university in Virginia, and the largest Christian university in the world. Located near the Blue Ridge Mountains on more than 7,000 acres in Lynchburg, Va., Liberty offers more than 500 unique programs of study from the associate to the doctoral level. More than 250 programs are offered online. Liberty’s mission is to train Champions for Christ with the values, knowledge, and skills essential for impacting tomorrow’s world.


News Article | March 2, 2017
Site: www.businesswire.com

MIAMI--(BUSINESS WIRE)--Miami Cardiac & Vascular Institute has completed its $120 million expansion project on the Baptist Hospital campus. The state-of-the-art facility includes additional space and cutting-edge technology, facilitating the creation of several new, specialized programs bringing together multidisciplinary teams of specialists to treat the cardiovascular system as a single entity. The expansion added 60,000 square feet of new space and included 40,000 square feet of renovations, nearly doubling the size of the Institute to 150,000 square feet in order to accommodate a growing number of patients and procedures. Since it was founded in 1987, Institute physicians have pioneered less-invasive techniques to treat aneurysms, stroke and heart disease, and have been part of many groundbreaking research trials. For 30 years, Miami Cardiac & Vascular Institute has been an integral innovation partner for Philips, a world leader in healthcare technologies, providing valuable clinical insights that have led to the development of industry-leading solutions such as the recently announced Philips Azurion Image Guided Therapy (IGT) system. The expansion includes a state-of-the-art Cath lab, representing the first North American installation of Azurion. The system is designed to anticipate what clinicians need, when they need it, to make procedures flow intuitively and support a superior patient experience. “This expansion allows us to be at the forefront of medical innovation and provides the most current treatment options for our patients, while at the same time, prepares us to be in the position to care for health problems we haven’t even encountered yet,” said Barry T. Katzen, M.D., Chief Medical Executive and founder of the Institute. “We are now able to conduct more research, offer new services and make discoveries that could transform how cardiovascular care is delivered.” Throughout its history, the Institute’s physicians have pioneered less-invasive techniques to treat aneurysms, stroke and heart disease, and have been part of many groundbreaking research trials. The newly expanded Institute, with its cutting-edge equipment and unique programs, allows our internationally respected physicians to continue their visionary work. One of the first elements of the three-year project was the expansion of Baptist Hospital’s Surgery Center, which now includes six large operating rooms dedicated to neuroscience, cardiac, vascular and robotic surgery. The Institute also added four new advanced endovascular suites with enlarged gallery viewing areas for enhanced teaching and learning opportunities. “This is the centerpiece of the expansion, the Center for Advanced Endovascular Therapies,” Dr. Katzen explained. “We wanted to create an environment in which we could do any type of predominantly image-guided procedure, where physicians of different disciplines could work together to create unique solutions for patients’ problems.” In designing interventional suites of the future, two of the new endovascular suites have glass walls and a video system that allow people to sit in a theater-style chair outside of the suite and control what they are watching using an iPad. Viewers from different disciplines or in training each can have their own unique user interface that allows them to pick and choose which parts of the procedure they want to watch, all with communication with the suites. Additionally, the Institute makeover created the National Center for Aneurysm Therapy — the first in the world — a Center for Structural Heart Therapy, Center for Critical Limb Ischemia and an Advanced Arrhythmia Therapy Center. It is here where physicians are doing research to discover more cardiovascular disease breakthroughs. “We are proud to open the doors of the new Miami Cardiac & Vascular Institute to our community,” said Brian E. Keeley, President and CEO of Baptist Health South Florida. “This expansion now provides even greater promise to our patients, with new state-of-the-art interventional procedure suites; an expansive, high-tech gallery for observation, diagnostics and greater teaching opportunities; and, research space for more than 120 clinical trials.” Miami Cardiac & Vascular Institute is the largest and most comprehensive cardiovascular facility in the region, consisting of 76 doctors and 1,100 employees system-wide serving 125,000 patients every year. “At Philips, we are committed to building a healthy society by creating solutions that are going to have a meaningful impact in improving human health, and this requires collaboration with pioneering organizations like Miami Cardiac & Vascular Institute,” said Brent Shafer, CEO of Philips North America. “The Institute’s clinical insights have been critical to the development of our Azurion technology, from understanding workflows and improving efficiencies, to understand how to improve the patient experience. Together, we are shaping the future of healthcare by making procedures safer and more efficient. This will not only help address the health issues in South Florida communities, it will allow us to apply those lessons globally to help tackle the challenges of rising healthcare costs and better access to care. Ultimately, we want to improve the patient experience and outcomes, one community at a time.” Miami Cardiac & Vascular Institute is the largest and most comprehensive cardiovascular facility in the region. The team of multilingual, multidisciplinary specialists has pioneered the development of minimally invasive techniques used to treat aneurysms, blockages in veins and arteries and holes in the heart. Miami Cardiac & Vascular Institute is part of Baptist Health South Florida, the largest healthcare organization in the region, with seven hospitals (Baptist Hospital, Baptist Children’s Hospital, Doctors Hospital, Homestead Hospital, Mariners Hospital, South Miami Hospital and West Kendall Baptist Hospital), nearly 50 outpatient and urgent care facilities, Baptist Health Medical Group, Baptist Health Quality Network and internationally renowned centers of excellence. The not-for-profit, faith-based Baptist Health has approximately 16,000 employees and 2,300 affiliated physicians. Baptist Health South Florida has been recognized by Fortune as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the World’s Most Ethical Companies. For more information, visit BaptistHealth.net and connect with us on Facebook at facebook.com/BaptistHealthSF and on Twitter and Instagram @BaptistHealthSF. Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 71,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.


News Article | March 2, 2017
Site: www.marketwired.com

MIAMI, FL--(Marketwired - March 02, 2017) - Miami Cardiac & Vascular Institute has completed its $120 million expansion project on the Baptist Hospital campus. The state-of-the-art facility includes additional space and cutting-edge technology, facilitating the creation of several new, specialized programs bringing together multidisciplinary teams of specialists to treat the cardiovascular system as a single entity. The expansion added 60,000 square feet of new space and included 40,000 square feet of renovations, nearly doubling the size of the Institute to 150,000 square feet in order to accommodate a growing number of patients and procedures. Since it was founded in 1987, Institute physicians have pioneered less-invasive techniques to treat aneurysms, stroke and heart disease, and have been part of many groundbreaking research trials. For 30 years, Miami Cardiac & Vascular Institute has been an integral innovation partner for Philips, a world leader in healthcare technologies, providing valuable clinical insights that have led to the development of industry-leading solutions such as the recently announced Philips Azurion Image Guided Therapy (IGT) system. The expansion includes a state-of-the-art Cath lab, representing the first North American installation of Azurion. The system is designed to anticipate what clinicians need, when they need it, to make procedures flow intuitively and support a superior patient experience. "This expansion allows us to be at the forefront of medical innovation and provides the most current treatment options for our patients, while at the same time, prepares us to be in the position to care for health problems we haven't even encountered yet," said Barry T. Katzen, M.D., Chief Medical Executive and founder of the Institute. "We are now able to conduct more research, offer new services and make discoveries that could transform how cardiovascular care is delivered." Throughout its history, the Institute's physicians have pioneered less-invasive techniques to treat aneurysms, stroke and heart disease, and have been part of many groundbreaking research trials. The newly expanded Institute, with its cutting-edge equipment and unique programs, allows our internationally respected physicians to continue their visionary work. One of the first elements of the three-year project was the expansion of Baptist Hospital's Surgery Center, which now includes six large operating rooms dedicated to neuroscience, cardiac, vascular and robotic surgery. The Institute also added four new advanced endovascular suites with enlarged gallery viewing areas for enhanced teaching and learning opportunities. "This is the centerpiece of the expansion, the Center for Advanced Endovascular Therapies," Dr. Katzen explained. "We wanted to create an environment in which we could do any type of predominantly image-guided procedure, where physicians of different disciplines could work together to create unique solutions for patients' problems." In designing interventional suites of the future, two of the new endovascular suites have glass walls and a video system that allow people to sit in a theater-style chair outside of the suite and control what they are watching using an iPad. Viewers from different disciplines or in training each can have their own unique user interface that allows them to pick and choose which parts of the procedure they want to watch, all with communication with the suites. Additionally, the Institute makeover created the National Center for Aneurysm Therapy -- the first in the world -- a Center for Structural Heart Therapy, Center for Critical Limb Ischemia and an Advanced Arrhythmia Therapy Center. It is here where physicians are doing research to discover more cardiovascular disease breakthroughs. "We are proud to open the doors of the new Miami Cardiac & Vascular Institute to our community," said Brian E. Keeley, President and CEO of Baptist Health South Florida. "This expansion now provides even greater promise to our patients, with new state-of-the-art interventional procedure suites; an expansive, high-tech gallery for observation, diagnostics and greater teaching opportunities; and, research space for more than 120 clinical trials." Miami Cardiac & Vascular Institute is the largest and most comprehensive cardiovascular facility in the region, consisting of 76 doctors and 1,100 employees system-wide serving 125,000 patients every year. "At Philips, we are committed to building a healthy society by creating solutions that are going to have a meaningful impact in improving human health, and this requires collaboration with pioneering organizations like Miami Cardiac & Vascular Institute," said Brent Shafer, CEO of Philips North America. "The Institute's clinical insights have been critical to the development of our Azurion technology, from understanding workflows and improving efficiencies, to understand how to improve the patient experience. Together, we are shaping the future of healthcare by making procedures safer and more efficient. This will not only help address the health issues in South Florida communities, it will allow us to apply those lessons globally to help tackle the challenges of rising healthcare costs and better access to care. Ultimately, we want to improve the patient experience and outcomes, one community at a time." Miami Cardiac & Vascular Institute is the largest and most comprehensive cardiovascular facility in the region. The team of multilingual, multidisciplinary specialists has pioneered the development of minimally invasive techniques used to treat aneurysms, blockages in veins and arteries and holes in the heart. Miami Cardiac & Vascular Institute is part of Baptist Health South Florida, the largest healthcare organization in the region, with seven hospitals (Baptist Hospital, Baptist Children's Hospital, Doctors Hospital, Homestead Hospital, Mariners Hospital, South Miami Hospital and West Kendall Baptist Hospital), nearly 50 outpatient and urgent care facilities, Baptist Health Medical Group, Baptist Health Quality Network and internationally renowned centers of excellence. The not-for-profit, faith-based Baptist Health has approximately 16,000 employees and 2,300 affiliated physicians. Baptist Health South Florida has been recognized by Fortune as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the World's Most Ethical Companies. For more information, visit BaptistHealth.net and connect with us on Facebook at facebook.com/BaptistHealthSF and on Twitter and Instagram @BaptistHealthSF. Royal Philips (NYSE: PHG) (AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 71,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.


Witt B.L.,Doctors Hospital | Hyer C.F.,The Surgical Center
Journal of Foot and Ankle Surgery | Year: 2012

Achilles tendinopathy is a clinical diagnosis characterized as a triad of symptoms including pain, swelling, and impaired performance of the diseased tendon. Achilles tendinopathy is divided into Achilles tendonitis and tendinosis based on histopathological examination. Achilles tendinosis is viewed microscopically as disorganized collagen, abnormal neovascularization, necrosis, and mucoid degeneration. Insertional Achilles tendinosis is a degenerative process of the tendon at the junction of the tendon and calcaneus. This disease is initially treated conservatively with activity modification, custom orthotic devices, heel lifts, and immobilization. After 3 to 6 months of conservative therapy has failed to alleviate symptoms, surgical management is indicated. Surgical management of insertional Achilles tendinosis includes Achilles tendon debridement, calcaneal exostosis ostectomy, and retrocalcaneal bursa excision. In this case series, we present 4 patients who underwent surgical management of insertional Achilles tendinosis with complete tendon detachment. All patients underwent reattachment of the Achilles tendon with the suture bridge technique. The Arthrex SutureBridge ® (Arthrex, Inc., Naples, FL) device uses a series of 4 suture anchors and FiberWire ® (Arthrex Inc.) to reattach the Achilles tendon to its calcaneal insertion. This hourglass pattern of FiberWire ® provides a greater area of tendon compression, consequently allowing greater stability and possible earlier return to weightbearing activities. The patients were followed up for approximately 2 years' duration. There were no intraoperative or postoperative complications. At final follow-up there was no evidence of Achilles tendon ruptures or device failures. All patients were able to return to their activities of daily living without the use of assistive devices. The patients' average visual analog pain scale was 1 (range 0 to 4), and their average foot functional index score was 3.41 (range 0 to 10.71). The suture bridge technique is a viable option for Achilles tendon repair after surgical management of insertional Achilles tendinosis. © 2012 American College of Foot and Ankle Surgeons.


Zvijac J.E.,Doctors Hospital | Toriscelli T.A.,Tampa Bay Buccaneers Football | Merrick S.,Tampa Bay Buccaneers Football | Kiebzak G.M.,Doctors Hospital
American Journal of Sports Medicine | Year: 2013

Background: There are conflicting reports regarding the association between isokinetic concentric quadriceps and hamstring strength deficits and ratios and risk for hamstring injuries in athletes. Purpose: To determine if isokinetic concentric Cybex data collected during the annual National Football League (NFL) Scouting Combine are predictive of hamstring injury in professional American football players during their first season. Study Design: Case-control study; Level of evidence, 3. Methods: All 32 NFL teams identified players selected during the first 5 rounds of the NFL annual draft who had hamstring injuries during their first professional season. Of these, 164 players with 172 injuries also had Cybex data from the previous years Combine. Analyses compared injured legs with contralateral uninjured legs and also injured players with uninjured controls using a database of Cybex data from all players who participated in the NFL Scouting Combine from 2006 to 2011. Results: No Cybex strength variable differentiated the injured legs from the contralateral uninjured legs or injured players from uninjured controls, even after taking into account days lost from activity. Mean ± SD peak torque for the injured and contralateral uninjured sides was as follows: 315.7 ± 70.0 and 313.5 ± 68.3 N.m, respectively (P = .773, paired t test), for quadriceps and 203.0 ± 42.4 and 205.3 ± 42.5 Nh.m, respectively (P = .608, paired t test), for hamstrings. The sensitivity and specificity for the hamstrings-to-quadriceps ratio predicting hamstring injury were 0.513 (95% confidence interval, 0.419-0.607) and 0.524 (0.495-0.554), indicating that the hamstrings-to- quadriceps ratio was not a useful predictor of injury (calculation used the mean ± SD ratio for injured legs, 0.656 ± 0.133). Side-to-side peak torque differences were also not predictive of injury, with more than a 10% difference (plus or minus) occurring commonly in both injured and uninjured players for quadriceps (53% prevalence for both injured and uninjured) and hamstrings (injured, 41% prevalence; uninjured, 43% prevalence). Conclusion: Isokinetic strength data collected from collegiate players at the NFL Scouting Combine were not useful for predicting risk of hamstring injury in subsequent professional NFL competition. These data call into question commonly accepted assumptions about risk factors for hamstring injury, at least for elite collegiate American football players, when the temporal relationship between Cybex testing and actual injury is several months. © 2013 The Author(s).

Loading Doctors Hospital collaborators
Loading Doctors Hospital collaborators